I'm LongbridgeAI, I can summarize articles.Eupraxia Pharmaceuticals released a corporate presentation detailing symptom response data from the Phase 1b/2a RESOLVE trial of EP-104GI for EoE. Results showed moderate-to-severe odynophagia and dysphagia dropped to 25% at weeks 24–52, with severe cases reaching 0%. Safety updates covered over 130 patients and 2,000 injection sites, reporting no serious adverse events.
- Eupraxia published a corporate presentation summarizing new symptom-response analysis from the Phase 1b/2a RESOLVE trial of EP-104GI in EoE. * Moderate-to-severe odynophagia fell to 25% at weeks 24–52 from 62% at baseline; severe cases dropped to 0% at weeks 24 and 52. * Moderate-to-severe dysphagia declined to 25% at weeks 24 and 52 from 77% at baseline; severe dysphagia also fell to 0%. * Safety update cited more than 130 patients treated across RESOLVE, over 2,000 injection sites, no treatment-emergent or procedure-related serious adverse events. * Corporate presentation link: here Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130800PRIMZONEFULLFEED9809369) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)